Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Loading stockData sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
Evotec SE Sponsored ADR represents shares in Evotec SE, a leading biotechnology company headquartered in Germany. Renowned for its innovative approach, Evotec SE specializes in drug discovery and development across several therapeutic areas, including neuroscience, oncology, and infectious diseases. The company leverages advanced technologies and data-driven solutions to accelerate the drug discovery process, aiming to provide novel content, platforms, and capabilities to its partners in the pharmaceutical and biotechnology sectors. As a Sponsored American Depository Receipt (ADR), it allows U.S. investors to gain exposure to Evotec SE without the complexities of investing directly in foreign stocks. This ADR facilitates access through platforms and brokerages familiar to U.S. traders, thus playing a crucial role in increasing the company's investor base outside Europe. In the global finance market, Evotec SE is recognized for its commitment to transforming the scientific innovation landscape by fostering strategic collaborations and investing in disruptive technologies.
$2.12
+$0.12 (+6.00%)
Live · 02:58 PM
The business is unprofitable at the operating level (-7.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 1.1% YoY. The question is whether this is cyclical or a structural shift.
Negative free cash flow of -€92M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
€745M
▼ -1.1% YoY
Net Income (TTM)
-€194M
▲ +47.2% YoY
Op. Margin
-11.06%
▲ +2.8pp YoY
ROIC
-3.32%
▲ +0.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-€53M
▲ +19.5% YoY
Op. Cash Flow (TTM)
€103M
▲ +71.8% YoY
Net Debt
-€15M
Net Cash Position
Cash & Equiv.
€463M
3Y CAGR: +1.6%
Continue Research
Evotec SE Sponsored ADR (EVO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Evotec SE Sponsored ADR scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Evotec SE Sponsored ADR scores 10 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -11.1% operating margin and a -3.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh EVO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.